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Supplementary Methods
Machine learning algorithms
Random Forest is an ensemble supervised learning method that is based on the construction
of  a  number  of  small/simple  base  predictors  using  decision  trees  (forest),  outputting  the
average prediction in case of regression tasks or the mode in case of classification.
Supplementary Figures
Figure S1: Distribution of experimental pharmacokinetics parameters for dendrimer 
constructs on the database.
Figure S2: Predicting the percentage of dose that is recovered in the liver and urine. The
graphs depict the regression plot between experimental and predicted %Doses for Liver (left-
hand side graph) and Urine (right-hand side graph), which obtained of up to r=0.87 after 10%
 outliers were removed (shown in red).
Figure S3: ROC curves dendrimer construct classification according to liver uptake and 
urinary excretion. Both predictions achieved an accuracy of 80% on these tasks, achieving 
AUCs of 0.87 and 0.86 for urinary excretion and liver uptake, respectively.
Figure  S4: PCA analysis  for  he  Half  Life  data  set.  The  left-hand  figure  depicts  the
contribution of each feature to explain the variability of the data set. The right-hand figure
shows a histogram of the percentage of explained variance per feature.
Figure S5: dendPoint database. The figure depicts the web-based interface for browsing the
relational database linking dendrimer properties and pharmacokinetic behavior. By accessing
the browsing option (1), users have the option to show/hide different properties (2,3,4) as
well as download the full contents of the database (5).
Figure S6: dendPoint submission page. The figure depicts the web-based interface for job
submission.  By  selecting  the  prediction  mode  (1),  users  can  specify  different  construct
properties (2) and surface functional groups (3) prior to submission (4).
Figure S7: dendPoint result page for single dendrimer predictions. The figure depicts the
prediction result page for a single dendrimer. The predicted pharmacokinetic properties for a
user-defined dendrimer construct are exhibited in tabular format (1). The interface gives the
user the option to either run another prediction (2) or compare the current construct with
another one (3). Also a dendrimer depiction is available, showing the number of generations
(as concentric grey circles) and surface groups as spheres. A plasma concentration prediction
curve is also provided (5).
Figure S8: dendPoint result page for dendrimer comparison. The figure depicts the prediction
result  page  for  comparing  pharmacokinetics  of  two  dendrimers.  The  predicted
pharmacokinetic  properties  are  exhibited  in  tabular  format  for  both  dendrimers  (1).  The
plasma  concentration  prediction  curves  for  both  constructs  are  also  provided  (2).  The
dendrimer  depictions  are  plotted  side-by-side,  showing  the  number  of  generations  (as
concentric grey circles) and surface groups as spheres (3-4).
Table S1. Summary of structural characteristics and pharmacokinetic properties for dendrimers that were included in the database.
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Surface characteristics PK parameters
Triazineh 2 10 (5) 14 6 (NH2), 8(OH) - 0 0 73 100 1 9 (2) 10 (2) 1
Triazineh 2 13 (2) 11 3 (NH2), 8 (OH) - 0 0 30 43 2.7 10 (2) 12 (2) 1
Triazineh 2 14 (0.6) 10 2 (NH2), 8 (OH) - 0 0 11 27 4.9 16 (2) 16 (2) 1
Triazineh 2 9 (2) 15 3 (NH2), 12 (drug) pac 0 0 39f 15 14g 35 (3) 11 (2) 2
Triazineh 2 8 (2) 16 4 (NH2), 12 (drug) pac 0 0 37 19 9g 55 (3) 22 (2) 2
Triazineh 2 6.5 (2) 17.5 5.5 (NH2), 12 (drug) pac 0 0 34 20 6g 41 (3) 10 (2) 2
Triazineh 2 6.5 (5) 17.5 1.5 (NH2), 16 (drug) pac 0 0 61 38 1.4 5 (2) 20 (2) 3
PAMAM 5 0 128 128 (OH) - 0 0 29 3 500g - 12 (1) 4
PAMAM 6 0 256 256 (OH) - 0 0 58 4 250g - 35 (1) 4
PAMAM 7 0 512 512 (OH) - 0 0 117 6 50g - 7 (1) 4
PAMAM 5 10 (2) 118 74 (Ac), 44 (NH2) - + 0 52 14g 2g 2 (2) 15 (2) 5
PAMAM 4 0 64 7 (NH2), 57 (do3a-
Gd)
- 0 0 50 72g 13g 35 (2) 40(2) 6
PAMAM 5 0 128 10 (DTPA-Tc), 81 
(Ac), 9 (biotin), 28 
(NH2)
- 0 0 ~41 19g* 12g - 57 (0.25) 7
PAMAM 3 12 (5) 12 2 (NH2), 10 (Do3a-
Gd)
- 0 0 69 20 - - 8 8
PAMAM 3 9 (2) 15 15 (Do3a-Gd) - 0 0 33 3 - - 4 8
PAMAM 2 3 (5) 9 9 (Do3a-Gd) - 0 0 24 0.6 - 38 1 8
PAMAM 2 7 (2) 5 5 (D03a-Gd) - 0 0 21 6 - 30 7 8
PAMAM 4 60 (5) 4 4 (Ac) - 0 0 334 78g 1g - 6 (1) 9
PAMAM 5 110 (2) 5 5 (Ac) - 0 0 284 31g 3g - 7 (1) 9
PAMAM 4 63 (2) 1 1 (Ac) - 0 0 162 41g 3 - 7(1) 9
PAMAM 4 0 64 64 (Ac) - 0 0 36 2g 36g - 4(1) 9
PAMAM 3 0 32 29 (NH2), Cy3 (3) - +++ 0 8 2 40g - 4 (0.25) 10
PAMAM 3 24 (1) 8 5 (NH2), Cy3 (3) - 0 0 33 18 3g - 4 (0.25) 10
polyester 3 8 (20) 8 8 (OH) - 0 + 160 50 2 7(2) 2(0.4) 11
polyester 2 4 (20) 4 4 (OH) - 0 ++ 87 25 3 10(2) 2(0.4) 11
polyester 3 8 (10) 8 8 (OH) - 0 + 85 40 2 2(2) 6(0.4) 11
polyester 3 8 (5) 8 8 (OH) - 0 + 45 31 3 3(2) 4(0.4) 11
polyester 1 2 (20) 2 2 (OH) - 0 +++ 44 1 152 20(2) 2(0.4) 11
polyester 2 4 (10) 4 4 (OH) - 0 ++ 43 26 4 34(2) 6(0.4) 11
polyester 2 4 (5) 4 4 (OH) - 0 ++ 23 11 21 22(2) 2(0.4) 11
polyester 1 2 (10) 2 2 (OH) - 0 +++ 22 8 103 33(2) 1(0.4) 11
polyglycerol 2 0 16 16 (OH) - 0 0 6 16g 14g 55(0.04) 8(1) 12
polyglycerol 2 0 16 6 (SO3), 10 (OH) - - 0 9 1g 56g 5(0.04) 90(1) 12
polyglycerol 2 0 16 13 (SO3), 3 (OH) - -- 0 13 1g 64g 1(0.04) 76(1) 12
polylysine 5 32 (1) 32 32 (COOH) - - + 64 33 3 16 (5) 16(5) 13
polylysine 5 28 (1) 36 16 (NH2), 15 (drug),
5 (CNNH2)
dox + + 53 34 2 3(5) 9(5) 14
polylysine 5 28 (1) 36 16 (NH2), 20 (-
CNNH2)
- + + 45 22 3 4(5) 4(3) 14
polylysine 5 28 (1) 36 36 (NH2) - ++ + 41 29 14 4(3) 37(3) 14
polylysine 5 18 (1) 46 23 (NH2), 15 (drug),
8 (-CNNH2)
dox + + 36 35 2 13(5) 5(5) 14
polylysine 5 18 (1) 46 23 (NH2), 23 
(CNNH2)
- + + 31 25 3 16(5) 3(5) 14
polylysine 5 18 (1) 55 55 (NH2) - ++ + 27 30 2 24(3) 5(3) 14
polylysine 5 30 (1) 34 4 (NH2), 15 (-
CNNH2), 15 (drug)
dox 0 + 56 51 1 - - 15
polylysine 5 32 (1) 32 6 (NH2), 26 (drug) MTXotb 0 0 64 26 2 9 (5) 8(5) 16
polylysine 5 32 (1) 32 6 (NH2), 26 (drug) MTX - 0 64 1 24 2 (3) 52 (3) 16
polylysine 5 32 (1) 32 4 (NH2), 28 (drug) MTXotb 0 + 71 33 2 14 (5) 10(5) 16
polylysine 5 32 (1) 32 8 (NH2), 24 (drug) MTX - + 68 0.3 65 2 (3) 85(3) 16
polylysine 4 32 (0.57) 0 0 - 0 0 22 14 9 33 (1) 2 (1) 17
polylysine 4 16 (0.57) 16 16 (drug) MTXotb 0 0 21 0.4 173 29 (1) 1 (1) 17
polylysine 5 64 (0.57) 0 0 - 0 0 48 37 1 6 (5) 8 (5) 17
polylysine 5 32 (0.57) 32 32 (drug) MTXotb 0 0 42 24 5 2 (5) 10(5) 17
polylysine 3 8 (0.57) 8 8 (drug) MTXotb 0 0 11 0.1 443 56 (1) 1 (1) 17
polylysine 3 8 (1) 8 8 (drug) MTXotb 0 0 15 0.2 330 64 (1) 1(1) 17
polylysine 4 16 (1) 16 16 (drug) MTXotb 0 0 30 21 5 24(4) 7(4) 17
polylysine 4 16 (2.3) 16 16 (drug) MTXotb 0 0 47 34 2 8(5) 10(5) 17
polylysine 5 32 (1) 32 32 (drug) MTXotb 0 0 59 51 2 1(7) 12(7) 17
polylysine 4 16 (0.57) 16 16 (NH2) - ++ + 13 0.1 213 74 (1) 3(1) 18
polylysine 4 16 (0.57) 16 16 (Ac) - 0 + 14 0.1 1433 72(1) 0.3(1) 18
polylysine 4  32 (2) 0 0 - 0 + 68 75 1 3(7) 9(7) 19
polylysine 3 16 (2) 0 0 - 0 + 34 24 3 26 (5) 4(5) 19
polylysine 4 32 (0.57) 0 0 - 0 + 22 10 17 43(1) 2(1) 19
polylysine 4 32 (0.2) 0 0 - 0 + 11 0.7 383 80(1) 0(1) 19
polylysine 3 16 (0.2) 0 0 - 0 + 6 0.6 647 82(1) 0(1) 19
polylysine 4 0 32 32 (COOH) - -- + 5 0.9 71 25(1) 12(1) 20
polylysine 4 0 16 16 (SO4) - --- + 10 0.9 21 30 (1) 26(1) 20
polylysine 4 0 32 32 (SO4) - --- + 14 1 24 3(1) 49(1) 20
polylysine 4 0 32 32 ([SO4]2) - --- + 7 0.2 1736 63(1) 0(1) 20
polylysine 3 0 16 16 (NH2) - +++ + 2 0.1 1942 8(1) 5(1) 21
polylysine 4 0 32 32 (NH2) - +++ + 4 0.1 4630 4(1) 10(1) 21
polylysine 4 0 32 32 (NH2) - +++ + 4 0.1 2880 4(1) 24(1) 21
aDendrimer generation
bFunctionality or identity of chemical groups conjugated to non-PEGylated surface reactive sites
cSurface conjugated drugs representing paclitaxel (pac), doxorubicin (dox), α-carboxyl OtButylated methotrexate (MTXotb) and methotrexate
bearing unmodified α-carboxyl functionality (MTX).
dStrength of surface charge (from highly anionic [---] to highly cationic [+++]). Assigned based on discussion in the respective manuscripts or
based on the number and type of surface charge as well as surface PEG loading.
eStructural flexibility of the dendrimer (from relatively rigid [0] to highly flexible [+++]). Relative structural flexibility of each dendrimer
construct was assigned based on discussion in the respective manuscripts.
fExists as a 400 kDa aggregate in solution.
gPharmacokinetic parameters calculated based on data that was extrapolated from plasma concentration vs time curves shown in the manuscript.
hSurface treatment of the published triazine dendrimers has resulted in 24 available surface groups rather than the standard 16. 
*Represents a recalculated value since the value reported in the manuscript was not the correct terminal Half-life.
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